Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (DE:5Y6)
FRANKFURT:5Y6
Holding DE:5Y6?
Track your performance easily
5Y6 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.84 - €11.70
Previous Close€5.95
Volume0.00
Average Volume (3M)222.00
Market Cap
€419.30M
Enterprise Value€292.13M
Total Cash (Recent Filing)$143.21M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Oct 31, 2024EPS Estimate
-€0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding68,390,000
10 Day Avg. Volume63
30 Day Avg. Volume222
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.49
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-4.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
€36.13Price Target Upside507.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
COMPASS Pathways News
PremiumStock Analysis & Ideas
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 program in treatment-resistant depression has successfully passed another data safety monitoring board (DSMB) review.
Financial PerformanceCOMPASS' cash position at the end of 2Q24 was $228.6M, which is expected to provide runway to 2026.
Therapeutic DevelopmentCOMP360 has demonstrated potential in PTSD along with psychological support with promising top-line Phase 2 data reported.
Bears Say
Clinical TrialsEnrollment in COMP360's pivotal trial 1 (COMP 005) is advancing slower than expected due to varying speed of patient screening among trial sites.
FundingFurther development in PTSD would require incremental funding beyond the current cash runway.
Market SentimentStocks of companies that are developing psychedelic therapeutics have remained weak after the negative FDA Advisory Committee vote on Lykos' MDMA-assisted psychotherapy, and CMPS has not been immune to that dynamic.
---
Options Prices
Currently, No data available
---
Ownership Overview
36.03% Insiders
0.26% Mutual Funds
31.17% Other Institutional Investors
32.54% Public Companies and
Individual Investors
5Y6 FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €4.84 and its highest was €11.70 in the past 12 months.
What is COMPASS Pathways’s market cap?
Currently, no data Available
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Oct 31, 2024 which is in 34 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Aug 01, 2024. The company reported -€0.504 earnings per share for the quarter, missing the consensus estimate of -€0.485 by -€0.019.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -€0.51.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 68,388,190 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -€0.504 in its last earnings report, missing expectations of -€0.485. Following the earnings report the stock price went up 2.206%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Among the largest hedge funds holding COMPASS Pathways’s share is ARK Investment Management LLC. It holds COMPASS Pathways’s shares valued at 13M.
---
COMPASS Pathways Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€36.13 (507.27% Upside)
€36.13 (507.27% Upside)
Blogger Sentiment
Bullish
DE:5Y6 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.32%
12-Months-Change
Fundamentals
Return on Equity
-70.96%
Trailing 12-Months
Asset Growth
32.74%
Trailing 12-Months
Company Description
COMPASS Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
---
5Y6 Earnings Call
Q2 2024
0:00 / 0:00
---
5Y6 Stock 12 Month Forecast
Average Price Target
€36.13
▲(507.27% Upside)
Technical Analysis
COMPASS Pathways
―
Mind Medicine
―
ATAI Life Sciences
―
Relmada Therapeutics
―
Cybin
―
Best Analysts Covering 5Y6
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-28.37%
reiterated a buy rating last month
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -28.37% per trade.
---